TruAlt Bioenergy Q3 FY26: Revenue Up 70% to ₹730.86 Cr, Profit at ₹69.19 Cr
TruAlt Bioenergy reported Q3 FY26 total income of ₹730.86 crore, up 69.75% QoQ, and PAT of ₹69.19 crore. EBITDA increased 7.54% to ₹134.00 crore. The company commissioned grain integration capex and plans 24 new CBG units with Sumitomo and GAIL. A 100 million litres/annum SAF facility is planned, seeking ₹150 crore funding.
The substantial revenue growth, completion of major capex, and strategic expansion plans in high-growth areas like CBG and SAF are likely to have a significant impact on the company's future performance and market position.
The company reported significant year-on-year growth in total income and EBITDA, along with progress in key strategic segments like CBG and SAF, indicating a positive operational and financial trajectory.
TruAlt Bioenergy Limited announced its financial and operational performance for the quarter ended December 31, 2025 (Q3 FY26). The company reported a total income of ₹730.86 crore, a significant 69.75% increase quarter-on-quarter, driven by higher throughput from the commissioning of grain integration capital expenditure and expanded plant operations.
EBITDA rose to ₹134.00 crore, a 7.54% sequential growth, reflecting improved capacity utilization and operating leverage. Profit After Tax (PAT) stood at ₹69.19 crore for the quarter. During Q3 FY26, TruAlt completed a key phase of operating consolidation in the ethanol segment with the full commissioning of its planned capital expenditure for grain-based integration. Four of the company's five ethanol plants were operational, achieving capacity utilization of over 95% on operating days. Unit 5 received its Consent to Operate on December 17, 2025, enabling all ethanol plants to be fully operational.
The Compressed Biogas (CBG) segment showed strong performance with total income of ₹30.97 crore for the nine months ended December 31, 2025, alongside a 63% EBITDA margin and a 43% PAT margin. TruAlt plans to develop 24 greenfield CBG units over the next two to three years through joint ventures with Sumitomo Corporation and GAIL.
In the Sustainable Aviation Fuel (SAF) segment, the company is progressing with a technology licensing agreement with Honeywell UOP for a proposed 100 million litres per annum SAF facility in Andhra Pradesh. Discussions for potential equity participation with Sumitomo Corporation are also underway. TruAlt is seeking ₹150 crore of viability gap funding under the PM JI-VAN scheme for this project.
The biofuel retail segment has seen the commissioning of seven retail outlets within six months, with four more under development. The company aims to scale to approximately 75 outlets from FY27 onwards.
Commenting on the performance, Vijay Nirani, Managing Director, stated, "The third quarter reflects meaningful progress in strengthening TruAlt Bioenergy’s operating foundation and enhancing the quality of earnings. Margin expansion during the period underscores the benefits of scale, dual-feed integration and disciplined execution across the platform. The transition towards near year-round operations marks a structural shift for the business, improving operating predictability, efficiency and earnings visibility."
TruAlt Bioenergy is one of India’s largest biofuels producers and the country’s largest ethanol producer, with a diversified and integrated presence across the biofuels value chain.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.